# To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

> **NCT04706468** · PHASE2 · COMPLETED · sponsor: **TaiGen Biotechnology Co., Ltd.** · enrollment: 202 (actual)

## Conditions studied

- Influenza Virus Infection

## Interventions

- **DRUG:** TG-1000

## Key facts

- **NCT ID:** NCT04706468
- **Lead sponsor:** TaiGen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706468, "To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04706468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*